In the ongoing effort to combat prevalent childhood illnesses, an unexpected source has emerged in scientific research: the blood drawn from paediatricians. This seemingly unusual reservoir has proven to be exceptionally rich in powerful antibodies, holding significant potential for use as preventative treatments. Early findings indicate these antibodies have even surpassed established antibody therapies in their effectiveness against respiratory syncytial virus (RSV) and a common cold virus.
Paediatricians, by the very nature of their work, face near-constant exposure to respiratory viruses. This occupational characteristic positions them as a potentially underappreciated resource in the search for highly effective antibodies targeting such pathogens. While antibody therapies are currently available for infections like RSV—a virus that affects nearly every child by the age of two and can lead to serious breathing difficulties—these treatments typically only neutralize a limited number of strains. The discovery of broader-acting treatments now appears to be a tangible possibility.
A research initiative, involving scientists such as Hui Zhai from the Children’s Hospital of Chongqing Medical University, began by examining the blood of ten paediatricians who had accumulated over a decade of experience at their hospital. From this extensive screening, the researchers successfully identified 56 potent antibodies specifically targeting RSV. These antibodies were derived from the immune cells of the participating paediatricians.
Following this initial discovery, the researchers synthesized artificial versions of these antibodies. In laboratory tests, three of these artificial antibodies demonstrated particularly high activity against a wide array of RSV strains. Disturbingly, one of these three also proved effective in neutralizing human metapneumovirus. This virus belongs to the same family as RSV and is a frequent cause of common colds, though it can also result in severe illness in some young children.
Further investigations, conducted using mouse and rat models, yielded compelling results. Injections of these three paediatrician-derived antibodies, administered either individually or in combination, successfully prevented the animals from developing symptoms when exposed to RSV or human metapneumovirus. Notably, the antibodies sourced from paediatricians were up to 25 times more effective at blocking RSV compared to existing antibodies like nirsevimab and clesrovimab. Moreover, they demonstrated the ability to neutralize a broader spectrum of viral strains.
This phenomenon aligns with anecdotal observations among paediatricians, who often report a growing resilience to respiratory viruses throughout their careers. Trent Calcutt, a medical professional at Port Macquarie Base Hospital in Australia, notes, “I’ve been working with paediatric patients for 10 years now and in my first few years, I would probably get two to three notable respiratory illnesses per year, and now I can go a year without getting any.” This personal experience suggests a natural development of enhanced immunity over time.
Calcutt believes that the antibodies derived from paediatricians show sufficient promise to warrant further rigorous investigation through human clinical trials. He commented, “There are certainly stranger interventions out there, so I think this one is worth considering,” indicating an openness to novel therapeutic approaches.
Current strategies for infant protection against RSV involve two primary methods. The first is the administration of a vaccine to expectant mothers during pregnancy, which provides passive immunity to newborns. The second approach involves administering an injection of nirsevimab or clesrovimab to infants. These antibodies function by neutralizing the virus should a child contract it, thereby helping to mitigate severe symptoms. However, their efficacy is limited to certain RSV strains.
It is worth noting that nirsevimab and clesrovimab were developed through a similar process: screening the blood of adults who had previously experienced RSV infections. This method identified antibodies that the individuals’ immune systems had naturally produced in response to the virus. Currently, there is no approved vaccine or antibody therapy available for human metapneumovirus.
Journal Reference: Science Translational Medicine DOI: 10.1126/scitranslmed.adz4170